Cannabis, CBD & inflammation regulation

TL;DR

• CB2 activation dampens TNF-α, IL-1β, IL-6 (Vaughan 2021).
• CBD also works via PPAR-γ, independent of CB2.
• Relevant target: chronic low-grade inflammation, not acute DOMS.
• Don't confuse with NSAIDs — different mechanisms.

Is post-workout anti-inflammation even a good idea?

Acute inflammation is part of the training stimulus — chronically suppressing it (daily ibuprofen) can blunt adaptation. CBD acts more subtly and seems to interfere less with adaptation (Vaughan 2021).

Physiological mechanisms of cannabinoids in inflammatory processes

The endogenous cannabinoid system plays a fundamental role in regulating inflammatory responses in the human organism. Immune cells such as macrophages, T-cells, and B-cells exhibit a high density of cannabinoid receptors, particularly type two. When phytocannabinoid molecules bind to these receptors or modulate their activity, this can influence the release of pro-inflammatory messenger substances, so-called cytokines. In contrast to classic anti-inflammatory drugs, cannabinoids thus intervene directly in the cellular communication of the system, opening up new approaches for recovery after intense physical exertion.

In addition to direct receptor interaction, active substances such as cannabidiol also influence the breakdown of the body's own endocannabinoids, such as anandamide. By inhibiting certain enzymes, the concentration of these pain-relieving and regulatory substances in the tissue remains elevated for longer. This indirect effect spares the body's own resources and supports the restoration of physiological balance after microtrauma, such as occurs in the muscles during sporting activity. Research is increasingly focusing on the question of how this delicate control can influence tissue healing in the long term without completely suppressing the necessary training stimulus.

• Modulation of cytokine release via the activation of CB2 receptors on immune cells.
• Increase of endogenous anandamide concentration through the inhibition of enzymatic degradation processes.
• Support of cellular homeostasis after intense physical exertion.
• Subtle regulation instead of complete blockade of the body's natural inflammatory response.

Swiss legal framework and practice in sports

In Switzerland, the legal framework for the use of cannabis products is clearly defined. Products with a total THC content of less than one percent do not fall under the Narcotics Act and are freely available on the market. This applies to most CBD oils and sports creams used by athletes for recovery. However, athletes must exercise caution, as a strict zero-tolerance policy applies to road traffic, with a limit of 1.5 micrograms of THC per litre of blood. Even the regular consumption of seemingly THC-free products can, under certain circumstances, lead to an accumulation that exceeds this limit and compromises fitness to drive.

Since August 2022, it has also been possible for Swiss doctors to prescribe medical cannabis with a higher THC content without an exceptional permit from the Federal Office of Public Health (FOPH). This primarily concerns pain therapy and the treatment of chronic inflammatory diseases. For competitive athletes, the stance of anti-doping agencies is also crucial: while cannabidiol has been removed from the Prohibited List, all other natural and synthetic cannabinoids remain prohibited in competition. Seamless quality control of the preparations used is therefore essential to avoid unintentional violations due to contamination.

• Free sale of CBD products with a total THC content of less than one percent in Switzerland.
• Strict zero-tolerance in Swiss road traffic with a THC limit of 1.5 micrograms per litre of blood.
• Facilitated access to medical cannabis due to the elimination of the FOPH exceptional permit since August 2022.
• WADA compliance exclusively for pure cannabidiol, while other cannabinoids remain prohibited in competition.

Differentiated application: acute injury versus chronic overuse

When using cannabinoids, a strict distinction must be made between acute sports injuries and chronic symptoms of overuse. An acute injury such as a ligament sprain primarily requires the classic first-aid protocol of rest, ice, compression, and elevation. Although cannabinoids can play a supportive role in pain relief here, they do not replace an initial medical diagnosis or established acute therapies. The anti-inflammatory effect is often not fully desirable in this initial phase, as the acute inflammation initiates the necessary healing process of the damaged tissue.

The situation is different with chronic overuse injuries such as tendon irritation or persistent joint pain, which are due to ongoing, subclinical inflammation. Here, the regulating effect of cannabinoids can help break the vicious cycle of pain and inflammation without damaging the tissue structure, as is the case with the long-term use of classic painkillers. In these cases, application is usually systemic via oils or local via ointments; although the evidence is promising, it always requires individual adjustment due to limited clinical data.

• Acute injuries primarily require mechanical relief and established medical first aid.
• Chronic overuse injuries are better suited for the regulating approach of cannabinoids.
• Local application using creams focuses the effect directly on the affected joints and muscle groups.
• Avoiding the typical side effects of classic painkillers on the gastrointestinal tract during long-term use.

FAQ